By proceeding, you agree to our Terms of Use and Privacy Policy.
DMPK-BA site head East Coast
#monoclonalantibodies #drugmetabolism
#NorthAmerica
Responsible for developing DMPK-BA strategy for ADCs and novel biologics.
Executive Director
#monoclonalantibodies #bispecificantibodies
#Northamerica
Gang Yin is currently working as Executive Director at Sutro Biopharma, Inc.
CSO
#cancerresearch #monoclonalantibodies
Immunologist with over 30 years experience in developing antibody-based agents for the treatment and detection of cancer. Chief Scientific Officer at Elucida Oncology.
Senior Director - Bioconjugation Chemistry
#monoclonalantibodies #cancer
Dedicated and enthusiastic ADC field expert. Over 12 years of industrial experience in the development and pre-clinical evaluation of bioconjugates in small biotech and CRO/CDMO. Experienced group lea
Chief Technology Officer
#mucosalimmunology #inflammationresearch #monoclonalantibodies
#Europe
Sander Van Deventer had a critical role in the development of the first commercial monoclonal antibody (Remicade) the first commercial gene therapy in the Western world (Glybera).
Director, Gene Expression Strategies
#cell #biotechnology #monoclonalantibodies
Ph.D. in Cell Biology from Fordham University and Sloan Kettering Cancer Center in New York.Director of Cell Line Development at MacroGenics, Inc. (2002- present).
Head immunoassay analytical research development Belgium
#Lifesciences #Monoclonalantibodies
Vincent Dewar is a committed and creative professional with strong analytical skills. His objective is to produce added value for the company and people he works with using new technologies or paradig
Chief Scientific Officer
#monoclonalantibodies #proteinengineering
PhD with over 30 years of therapeutic Ab (I/O and autoimmune) and biological drug R&D experience. Demonstrated competency in basic research, antibody technology, target identification, biomarker and p